Clinical Trials Browser

Phase 1/2 × INDUSTRY × CTL019 chimeric antigen receptor × Clear all

NCT03896854 2023-11-29

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute